We’re excited to present our latest data on tumor-targeted antibody-drug conjugates (ADCs) at ESMO 2025 in Berlin. Join us to discover how our proprietary platform technologies are reshaping the future of targeted cancer therapies.
We’re excited to present our latest data on tumor-targeted antibody-drug conjugates (ADCs) at ESMO 2025 in Berlin. Join us to discover how our proprietary platform technologies are reshaping the future of targeted cancer therapies.
You are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information
